Skip to main content
. 2024 Feb 22;18(9):6845–6862. doi: 10.1021/acsnano.3c04471

Figure 7.

Figure 7

Nanoparticle vaccine activates antigen-specific and functional CD8+ T cells against MC38 neoantigens. (A) Vaccination and downstream analysis scheme. (B) Quantification of the frequency of Reps1-specific and Adpgk-specific CD8+ T cells in spleen after vaccination using peptide/MHC tetramer staining (mean ± SD; n = 7–8 mice/group; *P < 0.05, **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons). (C) Percentage of central and effector memory antigen-specific CD8+ T cells in spleen after vaccination (mean ± SD; n = 7–8 mice/group; ****P < 0.0001; two-way ANOVA with Tukey’s multiple comparisons). (D) Representative ICCS flow cytometry plots evaluating the percentage of IFNγ+TNFα+ CD8+ T cells after ex vivo restimulation of splenocytes with Reps1 (AQLANDVVL) or Adpgk (ASMTNMELM) peptides. (E) Quantification of flow cytometry data in D (mean ± SD; n = 7–8 mice/group; *P < 0.05, **P < 0.01; one-way ANOVA with Tukey’s multiple comparisons). (F) Representative ELISPOT wells after ex vivo restimulation of splenocytes with Reps1 (AQLANDVVL) or Adpgk (ASMTNMELM) peptides. (G) Quantification of images in F to determine the CD8+IFNγ+ T cell response (mean ± SD; n = 7–8 mice/group; *P < 0.05, **P < 0.01, ****P < 0.0001; one-way ANOVA with Tukey’s multiple comparisons).